Nateglinide treatment clinical study of type 2 diabetes.doc

 PAGE \* MERGEFORMAT 10 Nateglinide treatment clinical study of type 2 diabetes Of: Douzhi Xing Lan Yin-hua Zhao Yang Pu [Abstract] Objective To evaluate nateglinide tablets in the treatment of type 2 diabetes hypoglycemic efficacy and safety. Methods 50 patients with type 2 diabetes were randomly divided into two groups (nateglinide group of 25 patients) and control group (reggae 25 patients out Chennai), fasting blood glucose before and after treatment (FBG), postprandial 2 h blood glucose (PBG), glycosylated hemoglobin (HbAlc) and liver and renal function. Results There were FBG, 2 h PBG, HbAlc than those each before treatment (P lt;0.05), while the difference between the two groups was not significant (Pgt; 0.05). adverse reaction rate of the experimental group 12.0%, 8.0% in the control group, differences between the two groups was not significant (Pgt; 0.05) , mild gastrointestinal symptoms, and relieve itself. There were no liver and kidney dysfunction. Conclusion hypoglycemic effect of nateglinide tablets, and repaglinide considerable, adverse reactions are mild, is an effective and safe drop sugar drug. [Keywords:] that ? effects of type 2 diabetes Nateglinide (nateglinide) is a novel hypoglycemic agent, compounds for the phenylalanine, a non-sulfonylurea insulin secretion agent, the drug had a rapid onset and sustained role in a short time, hypoglycemic effect of good, bad few and mild reaction [1]. a number of studies have shown that strict control of blood glucose can reduce complications of diabetes. To understand the domestic nateglinide in type 2 diabetes in the clinical efficacy and safety, the experiment made that glibenclamide Chennai randomized, double-blind, positive drug (repaglinide) the principle of parallel control to observe the clinical efficacy of nateglinide. 1 Data and methods 1.1 General Information The group were all patients in our hospital clinic or hospital. Inclusion criteria: meet the 1999 WHO dia